NEWS
Gustave Roussy Liquid Biopsy Day, Paris
June 4, 2026
Adelis sponsors the 2nd Gustave Roussy liquid biopsy symposium Paris 2026, featuring leading experts in cfDNA fragmentomics, MRD monitoring, and precision oncology.
Adelis pioneers Smart Fragmentomics, enabling direct cfDNA fragment profiling from only 50 µL of plasma without DNA extraction. Powered by the BIABooster multi-capillary electrophoresis platform, this approach reveals high-resolution fragmentation signatures to accelerate biomarker discovery, support liquid biopsy research, and advance translational oncology and precision medicine.
Our solutions are created for your needs, offering you simplicity, ergonomics and time saving. Adelis aims to answer today and tomorrow challenges, particularly the growing global demand for high sensitivity analytical methods to measure DNA size and concentration in biological matrices. This trend is particularly true in the field of oncology and the study of cfDNA.
Online concentration
Size separation
Online purification
Online collection
BIABooster hub is based on the use of μLAS technology (micro Laboratory for Analysis and Separation of DNA). It enables simultaneous concentration and separation instead of sequential steps with classical methods.
µLAS Technology is a new paradigm for DNA handling which usually requires a large number of operations involving multiple technologies.
In oncology, the use of cfDNA as a biomarker allows to differentiate cancer patients from healthy people and to follow the efficiency of a drug therapy. With leading academic and health organisations, our clinical research programmes aim to develop cfDNA size and concentration profiling for treatment results prediction and cancer detection tests.
